Search

Author/Creator Shain, Kenneth

1. An open‐label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma. (12th March 2015)

Authors:
Nishihori, Taiga; Baz, Rachid; Shain, Kenneth; Kim, Jongphil; Ochoa‐Bayona, Jose L.; Yue, Binglin; Sullivan, Daniel; Dalton, William; Alsina, Melissa
Journal:
European journal of haematology
Issue:
Volume 95:Number 5(2015:Nov.)
Page Start:
426
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Issue 11 (4th October 2019)

Authors:
Ghobrial, Irene M.; Liu, Chia‐Jen; Zavidij, Oksana; Azab, Abdel K.; Baz, Rachid; Laubach, Jacob P.; Mishima, Yuji; Armand, Philippe; Munshi, Nikhil C.; Basile, Frank; Constantine, Michael; Vredenburgh, James; Boruchov, Adam; Crilley, Pamela; Henrick, Patrick M.; Hornburg, Kalvis T. V.; Leblebjian...
Journal:
American journal of hematology
Issue:
Volume 94:Issue 11(2019:Nov.)
Page Start:
1244
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. Issue 1 (December 2016)

Authors:
Turner, Joel; Dawson, Jana; Grant, Steven; Shain, Kenneth; Dalton, William; Dai, Yun; Meads, Mark; Baz, Rachid; Kauffman, Michael; Shacham, Sharon; Sullivan, Daniel
Journal:
Journal of hematology & oncology
Issue:
Volume 9:Issue 1(2016)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗